Fuji Pharma Of Japan To Buy Control Of Thai Contract Drug Maker OLIC
This article was originally published in PharmAsia News
Executive Summary
Japan’s Fuji Pharma plans to acquire OLIC, Thailand’s largest contract pharmaceutical maker, for just over $54 million, giving the Japanese firm total control.
You may also be interested in...
FDA Slams Teligent For Lax Approach To Complaint Handling And Stability Testing
Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.
Device Week, 12 December 2019 – Global Insulin Pump Market Will Face Fierce Rivalry Among Major Players In 2020
In this edition of Device Week, Medtech Insight's deputy editor Reed Miller chats with managing editor Marion Webb about her latest in-depth Market Intel story, the first part of a two-part series focusing on the competitive landscape of the global insulin pump market.
Can COMPASS Bring Psilocybin’s ‘Magic’ To Depression?
COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its CEO tells Scrip.
Need a specific report? 1000+ reports available
Buy Reports